Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 72.10% is 13% above its 5-year average of 63.71%, near the high end of its 5-year range (33.58%–78.04%).
As of the fiscal period ended Tuesday, June 30, 2026. 4.73% above its 12-month average of 68.84%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 72.10%.
DEBT TO ASSETS RATIO
72.10%
DEBT TO ASSETS RATIO AVG TTM
68.84%
DEBT TO ASSETS RATIO AVG 3Y
71.18%
DEBT TO ASSETS RATIO AVG 5Y
63.71%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+4.73%
CURRENT VS 3Y AVG
+1.30%
CURRENT VS 5Y AVG
+13.17%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+80011.67%
vs the sector median at left
NeuroPace, Inc.
Market Cap
$431.97M
Debt to Assets Ratio
72.10%
TTM Avg
68.84%
3Y Avg
71.18%
5Y Avg
63.71%
Market Cap
$435.61M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$426.51M
Debt to Assets Ratio
0.69%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$438.07M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$439.55M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$422.86M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$422.72M
Debt to Assets Ratio
0.17%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$442.34M
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NeuroPace, Inc. (NPCE) | $431.97M | 72.10% | 68.84% | 71.18% | 63.71% |
| YD Bio Limited Ordinary Shares (YDES)vs › | $435.61M | 0.00% | N/A | N/A | N/A |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $426.51M | 0.69% | N/A | N/A | N/A |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $438.07M | 0.00% | N/A | N/A | N/A |
| Assembly Biosciences, Inc. (ASMB)vs › | $439.55M | 0.01% | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $424.10M | 0.33% | N/A | N/A | N/A |
| Tectonic Therapeutic, Inc. (TECX)vs › | $422.86M | 0.02% | N/A | N/A | N/A |
| Tilray Brands, Inc. (TLRY)vs › | $422.72M | 0.17% | N/A | N/A | N/A |
| Ovid Therapeutics Inc. (OVID)vs › | $442.34M | 0.05% | N/A | N/A | N/A |
| Prothena Corporation plc (PRTA)vs › | $419.87M | 0.02% | N/A | N/A | N/A |
Debt/Assets
72.1%
Debt/Equity
5.88
Current Ratio
4.94
Interest Coverage
-2.2x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 72.10% |
| 2026-03-31 | 71.25% |
| 2025-12-31 | 67.10% |
| 2025-09-30 | 66.37% |
| 2025-06-30 | 67.40% |
| 2025-03-31 | 66.38% |
| 2024-12-31 | 77.49% |
| 2024-09-30 | 76.32% |
| 2024-06-30 | 78.04% |
| 2024-03-31 | 73.93% |
| 2023-12-31 | 67.25% |
| 2023-09-30 | 72.20% |
| 2023-06-30 | 69.47% |
| 2023-03-31 | 66.22% |
| 2022-12-31 | 61.14% |
| 2022-09-30 | 56.73% |
| 2022-06-30 | 48.23% |
| 2022-03-31 | 44.17% |
| 2021-12-31 | 37.32% |
| 2021-09-30 | 35.10% |
| 2021-06-30 | 33.58% |
| 2021-03-31 | 105.62% |
| 2020-12-31 | 94.48% |
